Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2020

01-05-2020 | Hepatitis C | Original Article

Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients

Authors: Shu-Fen Wu, Chih-Wei Tseng, Yun-Che Ho, Yen-Chun Chen, Ping-Hung Ko, Yi-Ting He, Kuo-Chih Tseng

Published in: Digestive Diseases and Sciences | Issue 5/2020

Login to get access

Abstract

Backgrounds

Regulatory T cells (Tregs) affect the pathogenesis of chronic hepatitis C (CHC) infection.

Aims

This study evaluated the function of Tregs in CHC patients receiving the standard direct-acting antiviral agents (DAA) treatment.

Methods

CHC patients (n = 20) who received DAA treatment, clinical data, and function of Tregs were checked at baseline, Week 4, end of treatment (EOT), and 12 weeks after EOT (SVR 12). Treg-mediated inhibition was measured. The cytokine expression and fold change of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, IL-10, and transforming growth factor (TGF)-β with/without Treg inhibition were also detected.

Results

The cohort included 14 females with a mean age of 59.8 ± 11.5 years. Nineteen had HCV genotype 1. The HCV RNA level was 6.17 ± 0.70 log IU/mL. All patients reached the sustained virologic response. The frequency of CD4+Foxp3+T cells decreased from baseline to EOT and returned at SVR 12. The inhibitory function of Tregs decreased during treatment and then restored (baseline vs. EOT, P = 0.0393; EOT vs. SVR 12, P = 0.0052). The cytokine expression and fold change of IFN-γ and TNF-α were highest at EOT and then decreased at SVR 12. The fold change of IL-10 was lowest at EOT and then increased at SVR 12. The fold change of TGF-β was significantly increased at Week 4 and SVR 12 compared to baseline.

Conclusions

The frequency and inhibitory function of Tregs declined gradually from baseline to EOT and then increased from EOT to SVR 12 in CHC patients receiving DAA therapy. The expression of IFN-γ, TNF-α, IL-10, and TGF-β parallelled Treg function.
Literature
1.
go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.CrossRef Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.CrossRef
2.
go back to reference Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.CrossRef Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.CrossRef
3.
go back to reference Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401–412.CrossRef Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401–412.CrossRef
4.
go back to reference Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med.. 2001;345:41–52.CrossRef Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med.. 2001;345:41–52.CrossRef
5.
go back to reference European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018 J Hepatol. 2018. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018 J Hepatol. 2018.
6.
go back to reference Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.CrossRef Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.CrossRef
7.
go back to reference Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702–726.CrossRef Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702–726.CrossRef
8.
go back to reference Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:e24. Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:e24.
9.
go back to reference Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–232.CrossRef Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–232.CrossRef
10.
go back to reference Hartling HJ, Ballegaard VC, Nielsen NS, Gaardbo JC, Nielsen SD. Immune regulation in chronic hepatitis C virus infection Scand. Gastroenterol. 2016;51:1387–1397. Hartling HJ, Ballegaard VC, Nielsen NS, Gaardbo JC, Nielsen SD. Immune regulation in chronic hepatitis C virus infection Scand. Gastroenterol. 2016;51:1387–1397.
11.
go back to reference Jung MK, Shin EC. Regulatory T cells in hepatitis B and C virus infections. Immune Netw.. 2016;16:330–336.CrossRef Jung MK, Shin EC. Regulatory T cells in hepatitis B and C virus infections. Immune Netw.. 2016;16:330–336.CrossRef
12.
go back to reference Tseng KC, Ho YC, Hsieh YH, et al. Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol. 2012;47:823–833.CrossRef Tseng KC, Ho YC, Hsieh YH, et al. Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol. 2012;47:823–833.CrossRef
13.
go back to reference Tseng KC, Ho YC, Tseng CW, et al. Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin. Int J Infect Dis. 2017;58:8–17.CrossRef Tseng KC, Ho YC, Tseng CW, et al. Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin. Int J Infect Dis. 2017;58:8–17.CrossRef
14.
go back to reference Langhans B, Nischalke HD, Kramer B, et al. Increased peripheral CD4(+) regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. J Hepatol. 2017;66:888–896.CrossRef Langhans B, Nischalke HD, Kramer B, et al. Increased peripheral CD4(+) regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. J Hepatol. 2017;66:888–896.CrossRef
15.
go back to reference Comarmond C, Garrido M, Pol S, et al. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152:e2052.CrossRef Comarmond C, Garrido M, Pol S, et al. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152:e2052.CrossRef
16.
go back to reference Fard SN, Schietroma I, Scheri GC, et al. Direct-acting antiviral therapy enhances total CD4 + and CD8 + T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clin Res Hepatol Gastroenterol. 2017;42:319–329.CrossRef Fard SN, Schietroma I, Scheri GC, et al. Direct-acting antiviral therapy enhances total CD4 + and CD8 + T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clin Res Hepatol Gastroenterol. 2017;42:319–329.CrossRef
17.
go back to reference Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868.CrossRef Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868.CrossRef
18.
go back to reference Cramp ME, Carucci P, Rossol S, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut. 1999;44:424–429.CrossRef Cramp ME, Carucci P, Rossol S, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut. 1999;44:424–429.CrossRef
19.
go back to reference Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–352.CrossRef Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–352.CrossRef
20.
go back to reference Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity. 2006;25:195–201.CrossRef Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity. 2006;25:195–201.CrossRef
21.
go back to reference Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.CrossRef Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.CrossRef
22.
go back to reference Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–2091.CrossRef Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–2091.CrossRef
23.
go back to reference Gangaplara A, Martens C, Dahlstrom E, et al. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment. PLoS Pathog. 2018;14:e1006985.CrossRef Gangaplara A, Martens C, Dahlstrom E, et al. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment. PLoS Pathog. 2018;14:e1006985.CrossRef
Metadata
Title
Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients
Authors
Shu-Fen Wu
Chih-Wei Tseng
Yun-Che Ho
Yen-Chun Chen
Ping-Hung Ko
Yi-Ting He
Kuo-Chih Tseng
Publication date
01-05-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05850-w

Other articles of this Issue 5/2020

Digestive Diseases and Sciences 5/2020 Go to the issue